Patents Represented by Attorney John A. Lamerdin
-
Patent number: 8278422Abstract: Novel ?10 polypeptides and heterodimers thereof, and nucleic acid molecules encoding the same are disclosed. The invention also provides vectors, host cells, selective binding agents, and methods for producing ?10 polypeptides and heterodimeric forms thereof, specifically ?2/?10. Also provided for are methods for the treatment, diagnosis, amelioration, or prevention of diseases with ?10 polypeptides and ?2/?10 heterodimers or their respective binding agents.Type: GrantFiled: June 16, 2010Date of Patent: October 2, 2012Inventor: Christopher J. R. Paszty
-
Patent number: 8273707Abstract: The invention relates to a process for purifying a protein by mixing a protein preparation with a solution having a first salt and a second salt, wherein each salt has a different lyotropic value, and loading the mixture onto a hydrophobic interaction chromatography column. The dynamic capacity of the column for a protein using the two salt combination will be increased compared with the dynamic capacity of the column for either single salt alone.Type: GrantFiled: June 23, 2010Date of Patent: September 25, 2012Assignee: Amgen Inc.Inventors: Anna Senczuk, Ralph Klinke
-
Patent number: 8217153Abstract: Various system and method embodiments of the present invention are directed to separating target molecules from complex solutions by affinity column chromatography using organic-solvent-containing eluants. In one embodiment of the present invention, an eluant containing an organic-solvent is used, at a first pH, to remove non-target solutes and suspended entities from an affinity chromatography column. The pH of the eluant is then changed to a second pH, and the organic-solvent-containing eluant is used to elute target molecules from the affinity column chromatography.Type: GrantFiled: January 25, 2010Date of Patent: July 10, 2012Assignee: Amgen Inc.Inventor: Joe Xin Hua Zhou
-
Patent number: 8188040Abstract: The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions.Type: GrantFiled: May 4, 2010Date of Patent: May 29, 2012Assignee: Amgen Inc.Inventors: Edward John Belouski, Murielle Marie Ellison, Agnes Eva Hamburger, Randy Ira Hecht, Yue-Sheng Li, Mark Leo Michaels, Jeonghoon Sun, Jing Xu
-
Patent number: 8163878Abstract: The present invention provides Tumor Endothelial Marker 5? (TEM5?) polypeptides and nucleic acid molecules encoding the same. The invention also provides selective binding agents, vectors, host cells, and methods for producing TEM5? polypeptides. The invention further provides pharmaceutical compositions and methods for the diagnosis, treatment, amelioration, or prevention of diseases, disorders, and conditions associated with TEM5? polypeptides.Type: GrantFiled: March 22, 2010Date of Patent: April 24, 2012Assignee: Amgen Inc.Inventor: Todd Juan
-
Patent number: 8148109Abstract: The present invention provides Interferon-Like (IFN-L) polypeptides and nucleic acid molecules encoding the same. The invention also provides selective binding agents, vectors, host cells, and methods for producing IFN-L polypeptides. The invention further provides pharmaceutical compositions and methods for the diagnosis, treatment, amelioration, and/or prevention of diseases, disorders, and conditions associated with IFN-L polypeptides.Type: GrantFiled: August 8, 2005Date of Patent: April 3, 2012Assignee: Amgen Inc.Inventors: Andrew Welcher, Duanzhi Wen, Michael Kelley
-
Patent number: 8071372Abstract: The present invention provides Tumor Endothelial Marker 5? (TEM5?) polypeptides and nucleic acid molecules encoding the same. The invention also provides selective binding agents, vectors, host cells, and methods for producing TEM5? polypeptides. The invention further provides pharmaceutical compositions and methods for the diagnosis, treatment, amelioration, or prevention of diseases, disorders, and conditions associated with TEM5? polypeptides.Type: GrantFiled: August 9, 2010Date of Patent: December 6, 2011Assignee: Amgen Inc.Inventor: Todd Juan
-
Patent number: 8034770Abstract: The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions.Type: GrantFiled: June 3, 2009Date of Patent: October 11, 2011Assignee: Amgen Inc.Inventors: Edward John Belouski, Murielle Marie Ellison, Agnes Eva Hamburger, Randy Ira Hecht, Yue-Sheng Li, Mark Leo Michaels, Jeonghoon Sun, Jing Xu
-
Patent number: 7994291Abstract: The present invention relates to a novel polypeptide encoding a protein which is the full length human ortholog of E3? ubiquitin ligase. The invention also relates to vector, host cells, antibodies and recombinant methods for producing the polypeptide. In addition, the invention discloses therapeutic, diagnostic and research utilities for these and related products.Type: GrantFiled: May 25, 2010Date of Patent: August 9, 2011Assignee: Amgen Inc.Inventors: Hui-Quan Han, Keith Kwak
-
Patent number: 7910709Abstract: Novel ?10 polypeptides and heterodimers thereof, and nucleic acid molecules encoding the same are disclosed. The invention also provides vectors, host cells, selective binding agents, and methods for producing ?10 polypeptides and heterodimeric forms thereof, specifically ?2/?10. Also provided for are methods for the treatment, diagnosis, amelioration, or prevention of diseases with ?10 polypeptides and ?2/?10 heterodimers or their respective binding agents.Type: GrantFiled: February 27, 2008Date of Patent: March 22, 2011Assignee: Amgen Inc.Inventor: Christopher J. R. Paszty
-
Patent number: 7883868Abstract: Novel ?10 polypeptides and heterodimers thereof, and nucleic acid molecules encoding the same are disclosed. The invention also provides vectors, host cells, selective binding agents, and methods for producing ?10 polypeptides and heterodimeric forms thereof, specifically ?2/?10. Also provided for are methods for the treatment, diagnosis, amelioration, or prevention of diseases with ?10 polypeptides and ?2/?10 heterodimers or their respective binding agents.Type: GrantFiled: February 27, 2008Date of Patent: February 8, 2011Assignee: Amgen Inc.Inventor: Christopher J. R. Paszty
-
Patent number: 7834162Abstract: Various system and method embodiments of the present invention are directed to separating target molecules from complex solutions by affinity column chromatography using organic-solvent-containing eluants. In one embodiment of the present invention, an eluant containing an organic-solvent is used, at a first pH, to remove non-target solutes and suspended entities from an affinity chromatography column. The pH of the eluant is then changed to a second pH, and the organic-solvent-containing eluant is used to elute target molecules from the affinity column chromatography.Type: GrantFiled: January 5, 2007Date of Patent: November 16, 2010Assignee: Amgen Inc.Inventor: Joe Xin Hua Zhou
-
Patent number: 7811791Abstract: The present invention provides Interferon-Like (IFN-L) polypeptides and nucleic acid molecules encoding the same. The invention also provides selective binding agents, vectors, host cells, and methods for producing IFN-L polypeptides. The invention further provides pharmaceutical compositions and methods for the diagnosis, treatment, amelioration, and/or prevention of diseases, disorders, and conditions associated with IFN-L polypeptides.Type: GrantFiled: October 29, 2004Date of Patent: October 12, 2010Assignee: Amgen Inc.Inventors: Andrew Welcher, Duanzhi Wen, Michael Kelly
-
Patent number: 7794970Abstract: Methods for generating F(ab?)2 fragments from antibodies using thermolysin as well as F(ab?)2 fragments and compositions comprising F(ab?)2 fragments generated by the method are described.Type: GrantFiled: September 18, 2006Date of Patent: September 14, 2010Assignee: Amgen Inc.Inventors: John O. Hui, Mitsuru Haniu, Hsieng Sen Lu
-
Patent number: 7745586Abstract: The present invention relates to a novel polypeptide encoding a protein which is the full length human ortholog of E3? ubiquitin ligase. The invention also relates to vector, host cells, antibodies and recombinant methods for producing the polypeptide. In addition, the invention discloses therapeutic, diagnostic and research utilities for these and related products.Type: GrantFiled: August 6, 2008Date of Patent: June 29, 2010Assignee: Amgen Inc.Inventors: Hui-Quan Han, Keith Kwak
-
Patent number: 7735525Abstract: A thermally insulated apparatus provides a substantially adiabatic environment for elevated temperature liquid chromatography applications. The thermally insulated apparatus minimizes or eliminates temperature gradients between columns and mobile phases, and maintains a temperature at or near the set point of an operably coupled heating means. The apparatus is also effective when used in conjunction with a liquid mobile phase heater such as those provided by an HPLC column compartment or a metal capillary of sufficient length to heat the liquid mobile phase.Type: GrantFiled: November 14, 2006Date of Patent: June 15, 2010Assignee: Amgen Inc.Inventors: Morlan H. Lunsford, Julian S. Osaki, Glen J. Salle, Christopher C. Corpuz
-
Patent number: 7662930Abstract: Various embodiments of the present invention are directed to multi-step systems and methods for target-molecule purification that employ column-chromatography-based and/or membrane-filtration-based polishing steps. In one described embodiment of the present invention, a target-protein-containing eluate having a high residual salt concentration is collected from a first chromatography column prepared with an affinity-chromatography resin, loaded onto a second chromatography column prepared with a cation-exchange resin, and eluted from the second cation-exchange column using a buffer in which a time-dependent pH gradient is established. In another described embodiment of the present invention, a partially purified target-protein-containing eluate is collected from a chromatography column and further purified by passing the target-protein-containing eluate through a salt-tolerant anion exchanger.Type: GrantFiled: December 6, 2006Date of Patent: February 16, 2010Assignee: AMGEN Inc.Inventor: Joe Xin Hua Zhou
-
Patent number: 7629144Abstract: The present invention provides novel Secreted Epithelial Colon Stromal-1 (Secs-1) polypeptides and nucleic acid molecules encoding the same. The invention also provides vectors, host cells, selective binding agents, and methods for producing Secs-1 polypeptides. The invention further provides methods for the treatment, diagnosis, amelioration, or prevention of diseases associated with Secs-1 polypeptides.Type: GrantFiled: February 28, 2006Date of Patent: December 8, 2009Assignee: Amgen Inc.Inventors: Anthony J. Polverino, Roland Luethy
-
Nucleic acid molecules encoding beta-like glycoprotein hormone polypeptides and heterodimers thereof
Patent number: 7514239Abstract: Novel ?10 polypeptides and heterodimers thereof, and nucleic acid molecules encoding the same are disclosed. The invention also provides vectors, host cells, selective binding agents, and methods for producing ?10 polypeptides and heterodimeric forms thereof, specifically ?2/?10. Also provided for are methods for the treatment, diagnosis, amelioration, or prevention of diseases with ?10 polypeptides and ?2/?10 heterodimers or their respective binding agents.Type: GrantFiled: March 27, 2001Date of Patent: April 7, 2009Assignee: Amgen Inc.Inventors: Christopher J. R. Paszty, Jin Cao, Dimitry M. Danilenko, Jianhua Gong, David C. Hill -
Patent number: 7358341Abstract: Novel ?10 polypeptides and heterodimers thereof, and nucleic acid molecules encoding the same are disclosed. The invention also provides vectors, host cells, selective binding agents, and methods for producing ?10 polypeptides and heterodimeric forms thereof, specifically ?2/?10. Also provided for are methods for the treatment, diagnosis, amelioration, or prevention of diseases with ?10 polypeptides and ?2/?10 heterodimers or their respective binding agents.Type: GrantFiled: May 28, 2003Date of Patent: April 15, 2008Assignee: Amgen Inc.Inventors: Christopher J. R. Paszty, Jin Cao, Dimitry M. Danilenko, Jianhua Gong, David C. Hill